

Statistical Analysis Plan MON 18-01, MON 18-02, and MON 18-03

A Prospective Study of a Single Injection Cross-linked Sodium Hyaluronate (MONOVISC) to Provide Symptomatic Relief of Osteoarthritis of Hip Joint (MON 18-01), Shoulder (MON 18-02), and Ankle (MON 18-03)

Protocol	Version	Issue Date
MON 18-01	V 1.0	15 July 2019
MON 18-02	V 2.0	19 Aug 2019
MON 18-03	V1.0	15 July 2019

SAP Date: 04 March 2021
Anika Therapeutics, Inc.

Prepared by: Gary Stevens, Ph.D.
DynaStat Consulting, Inc.

Approved by:

Adrian Orr

DocuSigned by:
Adrian Orr
C8F486137CFC451...

09-Mar-21

Anika Therapeutics, Inc.

Gary Stevens, Ph.D.

DocuSigned by:
Gary Stevens
AF94A45F4C1E441...

09-Mar-21

Dynastat Consulting, Inc.

Table of Contents

Contents

Table of Contents..... 2

1.0 Introduction..... 3

2.0 Study Design..... 3

3.0 Objectives 3

 Primary Endpoint: 3

 Secondary Endpoints: 3

 Exploratory Endpoints 4

 Safety Endpoint:..... 4

4.0 Statistical Methods in Protocol 5

 4.1 Statistical Methods..... 5

 4.1.1 Sample Size..... 5

 4.1.2 Primary Efficacy Endpoint 5

 4.1.3 Secondary Efficacy Endpoints 7

 4.1.4 Exploratory Endpoints 10

 4.2 Statistical Methods..... 11

 4.3 Demographic and Baseline Characteristics 11

 4.4 Adverse Events 11

 4.5 Subject Populations..... 11

 4.6 Additional Analyses..... 12

1.0 Introduction

This document presents the statistical analysis plan (SAP) for the Anika Therapeutics, Inc. protocols MON 18-01 (Hip), MON 18-02 (Shoulder), and MON 18-03 (Ankle). This SAP incorporates the data listings, summary tables, and statistical analyses. This document is based on the original final protocols and case report forms (CRFs) for each study.

The three studies are the same except for the anatomical area of interest and so all of the analyses will be consolidated into a single SAP.

2.0 Study Design

This is a prospective, post market clinical follow-up (PMCF) multi-center, open-label study to evaluate the residual risk of injections of MONOVISC for relief of pain in patients with a diagnosis of an osteoarthritic hip joint (MON 18-01), shoulder joint (MON 18-02), and ankle joint (MON 18-03).

The subjects in each of these study will be patients with a diagnosis of osteoarthritic (OA) joint who the investigator determines are appropriate candidates for treatment with a viscoelastic injection of MONOVISC.

In each study, up to 25 subjects will be enrolled at up to 20 investigational sites in the EU. Subject participation will last approximately 6 Months, with visits scheduled at Screening, Baseline, 1 month, 3 month and 6 months.

3.0 Objectives

The goal of these studies is to demonstrate the clinical improvement and safety in patients treated with MONOVISC for hip osteoarthritis, shoulder osteoarthritis, and ankle osteoarthritis. Specifically, this study will provide confirmation to the effectiveness and safety of MONOVISC at relieving the specified joint pain to 6 months post-treatment.

PRIMARY ENDPOINT:

- Reduction of index joint Numerical Rating Scale (NRS) pain on walking from baseline to 6 Months post injection (MON 18-01), joint pain from baseline to 6 Months post injection (MON 18-02), and pain on walking from baseline to 6 Months post injection (MON 18-01).

SECONDARY ENDPOINTS:

- Improvement in Lequesne Hip index joint from baseline to 6 months post injection. (MON 18-01 only)
- Improvement in DASH score for index joint from baseline to 6 months post injection (MON 18-02 only)

- Improvement in AOFAS index joint from baseline to 6 months post injection (MON 18-03 only).
- Improvement in Patient Global Assessment (PGA) from baseline to 6 months post injection.
- OMERACT-OARSI responder rate in the index joint at 6 months post injection.
- Time to treatment failure
- Reduction in Medication usage from baseline to 6 months post injection.

EXPLORATORY ENDPOINTS

Any comparisons across timepoints (baseline to 6 months) not described in the primary or secondary endpoints, including but not limited to:

- Demographics
- Medical History
- History of joint osteoarthritis
- Rescue Medication Use
- Treatment Failure
- Injection procedure
- Concomitant medications
- Non-drug therapy

SAFETY ENDPOINT:

The incidence, severity, and relationship to treatment of all Adverse Events (AE) will be collected from the treatment injection to the 6 month assessment.

4.0 Statistical Methods in Protocol

4.1 STATISTICAL METHODS

This Statistical Analysis Plan provides the details of the statistical analysis of the study data that is described in the protocol.

4.1.1 Sample Size

The primary analysis will be the mean change in index joint pain from baseline to 6 months as measured by the Numerical Rating Scale.

The hypothesis to be tested is:

$$H_0: \mu_{\text{DMON}} = 0 \text{ versus } H_A: \mu_{\text{DMON}} > 0.$$

In this hypothesis, μ_{DMON} is the mean change in pain on walking from baseline at 6 Months in MONOVISC treated patients.

The data will be analyzed via a one sample t-test.

It is assumed that a mean change in pain from baseline of 2 points represents a clinically significant improvement with a standard deviation of 2 - 2.5 points, for 80% power and alpha of 5% then a total of 15 subjects are required. To ensure sufficient subjects are available at the 6 month follow up, it is proposed to enroll and treat at least 25 subjects which should be more than adequate to demonstrate that treatment of the study population with MONOVISC would reduce joint pain at 6 months.

Single sites should not enroll more than 50% of the total enrollment.

4.1.2 Primary Efficacy Endpoint

4.1.2.1 The mean change in index joint Pain from baseline to 6 Months as measured with NRS comparing the Monovisc treated group to baseline measurements.

The primary analysis will be the mean change in index joint pain from baseline to 6 months as measured by the Numerical Rating Scale.

The hypothesis to be tested is:

$$H_0: \mu_{\text{DMON}} = 0 \text{ versus } H_A: \mu_{\text{DMON}} > 0.$$

In this hypothesis, μ_{DMON} is the mean change in pain from baseline at 6 Months in MONOVISC treated patients.

The data will be analyzed via a one sample t-test.

This will be analyzed using SAS PROC UNIVARIATE. ODS statements will be used to output the descriptive statistics and p-values into data sets that can be easily displayed using PROC REPORT.

The tables for this analysis will be displayed as follows showing all time points for reference:

This analysis will be performed for each of the protocols

Summary of Differences in Mean Responses over time -

Time Perios	Descriptive Statistic	Baseline Result	Visit Result	Change from Baseline
1 Week	N			
	Mean			
	Std.Drv			
	Median			
	(Min,Max)			
	p-value diff=0			
1 Month	N			
	Mean			
	Std.Drv			
	Median			
	(Min,Max)			
	p-value diff=0			
. . .				
6 Months	N			
	Mean			
	Std.Drv			
	Median			
	(Min,Max)			
	p-value diff=0			

4.1.3 Secondary Efficacy Endpoints

4.1.3.1 Improvement in Lequesne Hip index joint from baseline to 6 months post injection. (MON 18-01 only)

Since this is a secondary endpoint the data will be analyzed for each time point individually with no adjustments for multiplicity. Data will be analyzed via a one sample t-test on the difference between the month hip function score and the baseline hip function score. Formally, the hypothesis to be tested is:

$$H_0: \mu_{\text{DMON}} = 0 \text{ versus } H_A: \mu_{\text{DMON}} > 0.$$

In this hypothesis, μ_{DMON} is the mean change from baseline at a time point for Monovisc treated patients.

This will be analyzed using SAS PROC UNIVARIATE. ODS statements will be used to output the descriptive statistics and p-values into data sets that can be easily displayed using PROC REPORT.

This will be analyzed and tabled like the primary endpoint in section 4.1.2.1.

4.1.3.1 Improvement in DASH Shoulder index joint from baseline to 6 months post injection. (MON 18-02 only)

Since this is a secondary endpoint the data will be analyzed for each time point individually with no adjustments for multiplicity. Data will be analyzed via a one sample t-test on the difference between the month shoulder pain score and the baseline shoulder pain score. Formally, the hypothesis to be tested is:

$$H_0: \mu_{\text{DMON}} = 0 \text{ versus } H_A: \mu_{\text{DMON}} > 0.$$

In this hypothesis, μ_{DMON} is the mean change from baseline at a time point for Monovisc treated patients.

This will be analyzed using SAS PROC UNIVARIATE. ODS statements will be used to output the descriptive statistics and p-values into data sets that can be easily displayed using PROC REPORT.

This will be analyzed and tabled like the primary endpoint in section 4.1.2.1.

4.1.3.2 Improvement in AOFAS index joint from baseline to 6 months post injection (MON 18-03 only).

Since this is a secondary endpoint the data will be analyzed for each time point individually with no adjustments for multiplicity. Data will be analyzed via a one sample t-test on the difference between the month ankle pain score and the baseline ankle pain score. Formally, the hypothesis to be tested is:

$$H_0: \mu_{\text{DMON}} = 0 \text{ versus } H_A: \mu_{\text{DMON}} > 0.$$

In this hypothesis, μ_{DMON} is the mean change from baseline at the time points for Monovisc treated patients.

This will be analyzed using SAS PROC UNIVARIATE. ODS statements will be used to output the descriptive statistics and p-values into data sets that can be easily displayed using PROC REPORT.

This will be analyzed and tabled like the primary endpoint in section 4.1.2.1.

4.1.3.3 The mean and percent change in Patient Global Assessment from Baseline to 1 Months, 3 Months and 6 Months.

Since this is a secondary endpoint the data will be analyzed for each time point individually with no adjustments for multiplicity. Data will be analyzed via a one sample t-test on the difference between the month PGA score and the baseline PGA score. Formally, the hypothesis to be tested is:

$$H_0: \mu_{\text{DMON}} = 0 \text{ versus } H_A: \mu_{\text{DMON}} > 0.$$

In this hypothesis, μ_{DMON} is the mean change from baseline at the time points for Monovisc treated patients.

This will be analyzed using SAS PROC UNIVARIATE. ODS statements will be used to output the descriptive statistics and p-values into data sets that can be easily displayed using PROC REPORT.

This will be analyzed for each of the protocols and tabled like the primary endpoint in section 4.1.2.1.

4.1.3.4 Responder index based on OMERACT- OARSI responder index at 1 Month, 3 Months and 6 Months.

The response rate for each time point will be tabulated and exact 95% confidence intervals will be calculated.

This will be estimated and tested using PROC FREQ with the BINOMIAL option. The results will be displayed similar to the format below.

Summary of the OMERACT-OARSI Responder Rates at each visit and each protocol.

Parameter	1 Week	1 Month	3 Months	6 Months
Estimate n/N (%)				
95% Confidence Interval				

4.1.3.5 Time to Treatment Failure.

The time to treatment failure will be assessed via the estimation of the Kaplan-Meier curve. This will be done via the PROC LIFEREG procedure in SAS. The estimate of the median survival time and the 95% confidence intervals will be reported. This will be done for each protocol.

For all studies, a patient is considered a treatment failure if any of the following occur:

Corticosteroid injections
 Shock-wave therapy
 Dry Needling
 Nitroglycerin patches
 Prolotherapy (PrT).
 Platelet / PRP / BMAC injection
 Hyaluronic Acid.
 Surgical treatment – open or arthroscopic

4.1.3.6 Reduction in Pain Medication usage at 1 Month, 3 Months and 6 Months.

The reduction from screening -baseline period in the mean reduction of medication usage per day between each visit will be tabulated and 95% confidence intervals will be calculated.

Number of subjects taking rescue medication between each visit will be tabulated.

This will be estimated using PROC MEANS. The results will be tabled like the primary endpoint in section 4.1.2.1.

4.1.4 Exploratory Endpoints

Any comparisons across timepoints (baseline to 6 months) not described in the primary or secondary endpoints, including but not limited to:

- Demographics:
 - Male vs Female
 - Age ≤ 50 years vs > 50 years
- Medical History
 - With / without history of joint surgery
- History of joint osteoarthritis
 - With / without prior joint pathologies
- Injection procedure:
 - With / without guidance
- Concomitant medications
- Non-drug therapy
 - With / without non-drug therapy

Specifically, subset populations will be compared based on the primary endpoint result and OMAREACT OARSI responder index at 6 months for each subset.

For the exploratory analyses, the continuous variables will be summarized via descriptive statistics (n, mean, median, standard deviation, minimum, and maximum. The discrete variables will be summarized via counts and percents.

4.2 STATISTICAL METHODS

Tabulation of summary statistics, graphical presentations, and statistical analyses will be performed using SAS® software 9.4 or higher version. Where not otherwise specified, the last pre-treatment observation will be used as baseline for calculating post-treatment changes from baseline. The primary presentations and analyses will be based on data pooled across study centers. Relevant summaries for individual centers, or combinations of centers, may be presented for primary data. All testing and confidence intervals will use a significance level of 5%.

4.3 DEMOGRAPHIC AND BASELINE CHARACTERISTICS

All demographic and baseline characteristics will be tabulated by treatment group and a test of homogeneity between the treatment groups will be conducted. For continuous variables (e.g. age, height, weight) a one way ANOVA will be used. For categorical variables (e.g. gender, race), a Fisher's exact test or chi-squared test will be used. Medical history findings, physical examinations and concomitant medications will be tabulated by treatment group.

The baseline, Vital Signs, and BMI data will be summarized via descriptive statistics and tested for homogeneity using a one way ANOVA.

4.4 ADVERSE EVENTS

All AEs will be coded according to MedDRA. Safety assessments will include Treatment-Emergent Adverse Events (TEAEs) which are defined as AEs with an Investigator assessment of definitely, probably, or possibly related to CTM. TEAEs will be summarized with frequencies and percentages by system organ class and preferred term, severity, and relationship to study CTM for each treatment group. In summaries of TEAEs by severity and relationship to CTM for subjects reporting multiple episodes, all reported events will be included, not only the worst reported case. Serious Adverse Events will also be presented by relationship to the CTM.

The number of subjects with at least one AE will be tabulated for each treatment group. Differences between the treatment groups will be tested using Fisher's exact test. Then the number of AEs for each treatment group will also be tabulated.

The number of subjects and the number of AEs will be tabulated by severity, relationship, and local injection site specific events versus non local events.

4.5 SUBJECT POPULATIONS

All safety analyses will be conducted on all subjects who undergo treatment in any group.

The Safety Population will be defined as all subjects who undergo at least one Study Treatment, and the safety analysis will be performed on this population.

The primary analysis on the primary endpoint will be performed on the Intent to Treat (ITT) population, defined as all patients who were enrolled in the study. All Primary and Secondary endpoints will be analyzed using the ITT population.

A secondary analysis will be conducted on the Per Protocol (PP) population. Since the primary endpoint is at 6 Months, this is all subjects who complete the 6 Month visit and who do not have a major deviation from the protocol. For all other assessments, this is defined as the subjects who complete those assessments according to the protocol.

4.6 ADDITIONAL ANALYSES

All of the analyses are performed on the data with the specified covariates or other factors assumed in the model. If it is determined that certain factors may influence the outcomes of the endpoints, then additional analyses will be performed